**Name of journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 35972**

**Manuscript Type: LETTER TO THE EDITOR**

***S*-Adenosyl-L-methionine towards hepatitis C virus expression: Need to consider *S*-Adenosyl-L-methionine’s chemistry, physiology and pharmacokinetics**

Tsikas D *et al.* SAM towards HCV

Dimitrios Tsikas, Erik Hanff, Alexander Bollenbach

**Dimitrios Tsikas, Erik Hanff, Alexander Bollenbach,** Core Unit Proteomics, Hannover Medical School, Hannover 30623, Germany

**ORCID number:** Dimitrios Tsikas (0000-0001-6320-0956); Erik Hanff (0000-0002-4553-4001); Alexander Bollenbach (0000-0002-2642-806X).

**Author contributions:** Tsikas D, Hanff E and Bollenbach A wrote and revised the manuscript.

**Conflict-of-interest statement:** All listed authors in this manuscript do not have financial relationships to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Dimitrios Tsikas, Professor**, Core Unit Proteomics, Centre of Pharmacology and Toxicology**,** Hannover Medical School,Carl-Neuberg-Strasse 1, Hannover 30625, Germany. tsikas.dimitros@mh-hannover.de

**Telephone**: +49-511-5323984

**Received:** August 21, 2017

**Peer-review started:** August 22, 2017

**First decision:** September 21, 2017

**Revised:** September 25, 2017

**Accepted:** October 18, 2017

**Article in press:**

**Published online:**

**Abstract**

*S*-Adenosyl-L-methionine (SAM) is a cofactor serving as a methyl donor in numerous enzymatic reactions. It has been reported that SAM has the potential to modify antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus -expressing cells at millimolar concentrations. The efficacy of SAM at micromolar concentrations and the underlying mechanisms remain to be demonstrated.

**Key words:** *S*-Adenosyl-L-methionine; Bioavailability; Concentration; Liver

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *S*-Adenosyl-L-methionine (SAM) serves as a cofactor for enzymes that transfer its methyl group to nucleophilic functionalities of various biomolecules including DNA and RNA. Exogenous SAM has been shown to be a useful pharmacological agent in liver-associated diseases. SAM is a labile species, undergoes spontaneous decomposition in biological samples, and its oral bioavailability is only about 2%. Lozano-Sepulveda and colleagues observed that SAM modulates antioxidant enzymes, restores glutathione synthesis, and switches MAT1/MAT2 turnover in hepatitis C virus (HCV) expressing cells. The authors suggested that this may be a likely mechanism by which HCV expression is diminished by SAM. This SAM concentration range was chosen on the basis of cell viability experiments and is up to 1000 times higher than physiological intracellular. Other groups have used SAM in the concentration range 0-1000 nmol/L. The efficacy of SAM, its pharmacological effects towards HCV and possibly adverse effects beyond cell viability need to be elaborated in further studies using SAM concentrations much lower than 1 mmol/L.

Tsikas D, Hanff E, Bollenbach A.*S*-Adenosyl-L-methionine towards hepatitis C virus expression: Need to consider *S*-Adenosyl-L-methionine’s chemistry, physiology and pharmacokinetics. *World J Gastroenterol* 2017; In press

**TO THE EDITOR**

*S*-Adenosyl-L-methionine (SAM) is the common cofactor of methylating enzymes, the methyl transferases. These enzymes catalyze the transfer of the methyl group of SAM to various nucleophilic functionalities of low-molecular-mass and high-molecular-mass biomolecules. Catechol amines, DNA, RNA, and proteins are well-investigated substrates of methyl transferases. SAM deficiency is associated with many different pathogenic conditions including liver diseases, depression and inherited methylation disorders. SAM supplementation in such diseases is a therapeutic means[1-5]. Lozano-Sepulveda and colleagues recently reported in the *World Journal of Gastroenterology* that SAM decreased hepatitis C virus (HCV) -RNA levels by 50% to 70% and induced a synergistic antiviral effect with standard IFN treatment[6]. The authors found that SAM modulated several antioxidant enzymes (*e.g.,* superoxide dismutase-1 and -2, thioredoxin), restored glutathione (GSH) synthesis, and switched methionine adenosyltransferase (MAT) turnover in HCV-expressing cells. The study by Lozano-Sepulveda and colleagues adds to the pleiotropic effects of SAM. However, this study by Lozano-Sepulveda and colleagues suffers from a major limitation, namely the use of very high SAM concentrations (range, 1 - 5 mmol/L)[6]. The choice of this SAM concentration range appears arbitrary. Another study limitation is that no SAM concentration/dose-response experiments have been performed.

SAM is a physiological substance and is widely distributed in extracellular and intracellular compartments of the human body[7-11]. The concentration of SAM in plasma of healthy subjects is of the order of 150 nmol/L, seemingly independent of the concentration of total homocysteine[7]. The intracellular SAM concentration in human lymphocytes has been reported to be about 5 nmol/106 cells; in mouse liver the SAM content was determined to be 0.5 nmol/mg protein[7]. The latter values are close to those reported by others using different analytical methods[12]. In freshly isolated human erythrocytes the concentration of SAM is of the order of 4 µmol/L[13]. This value agrees with more recently reported median SAM concentrations in erythrocytes of diabetic (3.8 µmol/L) and non-diabetic (3.5 µmol/L) male and female subjects[14].

The pharmacokinetics of SAM has been frequently investigated in animals as well as in healthy and diseased humans[15-17]. The oral bioavailability of SAM is of the order of 1%-4%. Ingestion of 1000 mg SAM as tosylate disulfate salt resulted in maximum plasma SAM concentrations of about 2.5 µmol/L in men and women[3]. Intravenous injection of 1000 mg SAM resulted in maximum plasma SAM concentrations of about 211 µmol/L[15]. Another study found that oral administration of 10 mg SAM/kg body weight did not result in significant increases in systemic SAM concentration[16]. Thus, the SAM concentration range used in the Lozano-Sepulveda’s study[6] is almost 1000-fold higher than physiological and pharmacologically used SAM concentrations (0-1000 nmol/L), and even 5 – 25 times higher than plasma SAM concentrations from intravenously injected SAM.

Use of very high SAM concentrations in *in vitro* experiments, even if not toxic[6], may lead to entirely different or contradictory results than the use of physiological and pharmacological SAM concentrations[18]. Oral administration of radiolabeled SAM (*i.e.,* [*methyl*-14C]SAM) in mice resulted in radioactivity accumulation in the liver due to authentic [*methyl*-14C]SAM and [*methyl*-14C]phosphatidylcholine. The latter was found to be about 8 (after 60 min) and 25 (after 240 min) times higher concentrated than [*methyl*-14C]SAM[16]. In aqueous solution, SAM is unstable and decomposes spontaneously to its components including *S*-methylthioadenosine, adenosine, adenine, and homoserine lactone[19]. Above pH 6, SAM is chemically very labile. Its inherent reactivity towards nucleophilic functionalities of biomolecules such as DNA and proteins is about 1000 times higher than that of methylated folates[19]. These observations suggest that SAM does not only function as an universal cofactor in methyltransferases-catalyzed reactions, but also undergoes both spontaneous methylation reactions with various biomolecules and decomposition to species such as *S*-methylthioadenosine and homoserine lactone[19]. Possibly, SAM decomposes to additional substances with not yet known biological activities, albeit not necessarily acutely cell toxic. The decrease in total glutathione concentration in the HCV-expressing cells upon incubation with SAM at 1 mmol/L for 1 and 2 h seen by Lozano-Sepulveda *et al*[6] may be an indication of a (spontaneous) reaction of SAM with reduced glutathione (GSH) to form *S*-methyl-glutathione which cannot be detected by the Ellman’s method. At least in rat kidney proximal tubules, *S*-methyl-glutathione is rapidly degraded by -glutamyl-transpeptidase[20]. Measurement of oxidized glutathione, *i.e.,* glutathione disulfide (GSSG), is a much more suitable and direct approach to assess oxidative stress. Yet, no GSSG data were reported in the paper[6]. It is worth mentioning that SAM (at 4 mmol/L) can also inhibit thioredoxin-mediated protein disulfide reductase activity[20]. This and further reports[22,22] are supportive of the chemical lability of SAM that makes it a spontaneous unselective methylating agent. Spontaneous decomposition of SAM considerably contributes to *S*-adenosyl-homocysteine which is a potent inhibitor of methyltransferases including protein arginine methyltransferases[23].

Lozano-Sepulveda and colleagues reported in their article interesting results and proposed possible mechanisms for the explanation of the effects exerted by SAM in HCV-expressing cells seen in their study[6]. Yet, the SAM concentrations used in the study are difficult to be reached within cells even by intravenous injection of SAM salts. The high chemical reactivity of the *S*-methyl group of SAM towards biomolecules and its spontaneous decomposition is likely to bear potential adverse effects. The efficacy and the safety of SAM, especially its pharmacological effects towards HCV, need to be elaborated in further studies taken into consideration the pharmacokinetics of SAM. Use of SAM at mmol/L-concentrations may raise unrealizable expectations.

**REFERENCES**

1 **Williams AL**, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. *Clin Invest Med* 2005; **28**: 132-139 [PMID: 16021987]

2 **Panza F**, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Di Palo A, Imbimbo BP, Vendemiale G, Capurso A, Solfrizzi V. Polyunsaturated fatty acid and S-adenosylmethionine supplementation in predementia syndromes and Alzheimer's disease: a review. *ScientificWorldJournal* 2009; **9**: 373-389 [PMID: 19468660 DOI: 10.1100/tsw.2009.48]

3 **Guo T**, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. *PLoS One* 2015; **10**: e0122124 [PMID: 25774783 DOI: 10.1371/journal.pone.0122124]

4 **Xiao Y**, Su X, Huang W, Zhang J, Peng C, Huang H, Wu X, Huang H, Xia M, Ling W. Role of S-adenosylhomocysteine in cardiovascular disease and its potential epigenetic mechanism. *Int J Biochem Cell Biol* 2015; **67**: 158-166 [PMID: 26117455 DOI: 10.1016/j.biocel.2015.06.015]

5 **Barić I**, Staufner C, Augoustides-Savvopoulou P, Chien YH, Dobbelaere D, Grünert SC, Opladen T, Petković Ramadža D, Rakić B, Wedell A, Blom HJ. Consensus recommendations for the diagnosis, treatment and follow-up of inherited methylation disorders. *J Inherit Metab Dis* 2017; **40**: 5-20 [PMID: 27671891 DOI: 10.1007/s10545-016-9972-7]

6 **Lozano-Sepulveda SA,** Bautista-Osorio E, Merino-Mascorro JA, Varela-Rey M, Muñoz-Espinosa LE, Cordero-Perez P, Martinez-Chantar ML, Rivas-Estilla AM. S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells. *World J Gastroenterol* 2016; **22**: 3746-3757 [PMID: 27076759 DOI: 10.3748/wjg.v22.i14.3746]

7 **Melnyk S**, Pogribna M, Pogribny IP, Yi P, James SJ. Measurement of plasma and intracellular S-adenosylmethionine and S-adenosylhomocysteine utilizing coulometric electrochemical detection: alterations with plasma homocysteine and pyridoxal 5'-phosphate concentrations. *Clin Chem* 2000; **46**: 265-272 [PMID: 10657384]

8 **Stabler SP**, Allen RH. Quantification of serum and urinary S-adenosylmethionine and S-adenosylhomocysteine by stable-isotope-dilution liquid chromatography-mass spectrometry. *Clin Chem* 2004; **50**: 365-372 [PMID: 14656903 DOI: 10.1373/clinchem.2003.026252]

9 **Gellekink H**, van Oppenraaij-Emmerzaal D, van Rooij A, Struys EA, den Heijer M, Blom HJ. Stable-isotope dilution liquid chromatography-electrospray injection tandem mass spectrometry method for fast, selective measurement of S-adenosylmethionine and S-adenosylhomocysteine in plasma. *Clin Chem* 2005; **51**: 1487-1492 [PMID: 15919880 DOI: 10.1373/clinchem.2004..046995]

10 **Krijt J**, Dutá A, Kozich V. Determination of S-Adenosylmethionine and S-Adenosylhomocysteine by LC-MS/MS and evaluation of their stability in mice tissues. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; **877**: 2061-2066 [PMID: 19502114 DOI: 10.1016/j.jchromb.2009.05.039]

11 **Kirsch SH**, Knapp JP, Geisel J, Herrmann W, Obeid R. Simultaneous quantification of S-adenosyl methionine and S-adenosyl homocysteine in human plasma by stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009; **877**: 3865-3870 [PMID: 19828381 DOI: 10.1016/j.jchromb.2009.09.039]

12 **Henning SM**, McKee RW, Swendseid ME. Hepatic content of S-adenosylmethionine, S-adenosylhomocysteine and glutathione in rats receiving treatments modulating methyl donor availability. *J Nutr* 1989; **119**: 1478-1482 [PMID: 2531221]

13 **Barber JR**, Morimoto BH, Brunauer LS, Clarke S. Metabolism of S-adenosyl-L-methionine in intact human erythrocytes. *Biochim Biophys Acta* 1986; **886**: 361-372 [PMID: 3011117]

14 **Becker A**, Henry RM, Kostense PJ, Jakobs C, Teerlink T, Zweegman S, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Smulders YM, Stehouwer CD. Plasma homocysteine and S-adenosylmethionine in erythrocytes as determinants of carotid intima-media thickness: different effects in diabetic and non-diabetic individuals. The Hoorn Study. *Atherosclerosis* 2003; **169**: 323-330 [PMID: 12921985 DOI: 10.1016/S0021-9150(03)00199-0]

15 **Yang J**, He Y, Du YX, Tang LL, Wang GJ, Fawcett JP. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. *Clin Ther* 2009; **31**: 311-320 [PMID: 19302903 DOI: 10.1016/j.clinthera.2009.02.010]

16 **Stramentinoli G**, Gualano M, Galli-Kienle M. Intestinal absorption of S-adenosyl-L-methionine. *J Pharmacol Exp Ther* 1979; **209**: 323-326 [PMID: 439007]

17 **Kaye GL**, Blake JC, Burroughs AK. Metabolism of exogenous S-adenosyl-L-methionine in patients with liver disease. *Drugs* 1990; **40** Suppl 3: 124-128 [PMID: 2081477]

18 **Feld JJ**, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, Titerence R, Koh C, Cherepanov V, Heller T, Ghany MG, Park Y, Hoofnagle JH, Liang TJ. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. *Gastroenterology* 2011; **140**: 830-839 [PMID: 20854821 DOI: 10.1053/j.gastro.2010.09.010]

19 **Laurino P**, Tawfik DS. Spontaneous Emergence of S-Adenosylmethionine and the Evolution of Methylation. *Angew Chem Int Ed Engl* 2017; **56**: 343-345 [PMID: 27901309 DOI: 10.1002/anie.201609615]

20 **Wendel A**, Heinle H, Silbernagl S. The degradation of glutathione derivatives in the rat kidney. *Curr Probl Clin Biochem* 1977; **8**: 73-84 [PMID: 616383]

21 **Lakowski TM**, Frankel A. Sources of S-adenosyl-L-homocysteine background in measuring protein arginine N-methyltransferase activity using tandem mass spectrometry. *Anal Biochem* 2010; **396**: 158-160 [PMID: 19733141 DOI: 10.1016/j.ab.2009.08.043]

22 **Fernandes AP**, Wallenberg M, Gandin V, Misra S, Tisato F, Marzano C, Rigobello MP, Kumar S, Björnstedt M. Methylselenol formed by spontaneous methylation of selenide is a superior selenium substrate to the thioredoxin and glutaredoxin systems. *PLoS One* 2012; **7**: e50727 [PMID: 23226364 DOI: 10.1371/journal.pone.0050727]

23 **Casellas P**, Jeanteur P. Protein methylation in animal cells. I. Purification and properties of S-adenosyl-L-methionine:protein (arginine) N-methyltransferase from Krebs II ascites cells. *Biochim Biophys Acta* 1978; **519**: 243-254 [PMID: 27218]

**P-Reviewer:** Capasso R, Yanev SG **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Germany

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0